UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 77

Sortiert nach

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

The lancet oncology, 2018-04, Vol.19 (4), p.486-496

2018

Volltextzugriff (PDF)

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma

Haematologica (Roma), 2015-05, Vol.100 (5), p.670

2015

Volltextzugriff (PDF)

A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy

British journal of haematology, 2020-02, Vol.188 (3), p.404-412

2020

Volltextzugriff (PDF)

A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia

The oncologist (Dayton, Ohio), 2017-10, Vol.22 (10), p.1156-e111

2017

Volltextzugriff (PDF)

Self-reported adherence to lenalidomide as maintenance therpay for multiple myeloma after autologous stem cell transplantation

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e20046-e20046

2018

Volltextzugriff (PDF)

Myositis-like Chronic Graft Versus Host Disease: Case Series and Literature Review

Blood, 2017-12, Vol.130, p.5508-5508

2017

Volltextzugriff (PDF)

ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease

Journal of clinical oncology, 2021-06, Vol.39 (17), p.1888-1898

2021

Volltextzugriff (PDF)

Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients

Blood, 2010-11, Vol.116 (21), p.619-619

2010

Volltextzugriff (PDF)

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens

Journal of clinical oncology, 2015-11, Vol.33 (33), p.3921-3929

2015

Volltextzugriff (PDF)

Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Clinical cancer research, 2020-05, Vol.26 (9), p.2096-2103

2020

Volltextzugriff (PDF)

A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)

Blood, 2022-11, Vol.140 (Supplement 1), p.9457-9458

2022

Volltextzugriff (PDF)

Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study

Blood, 2020-11, Vol.136 (Supplement 1), p.50-52

2020

Volltextzugriff (PDF)

Comparison of Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation of G-CSF-Stimulated Bone Marrow Versus Non-Stimulated Bone Marrow Versus Peripheral Blood

Blood, 2017-12, Vol.130, p.5493-5493

2017

Volltextzugriff (PDF)

A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS8063-TPS8063

2023

Volltextzugriff (PDF)

Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study

Gynecologic oncology, 2004-12, Vol.95 (3), p.506-512

2004

Volltextzugriff (PDF)

Medulloblastoma in an Adult With Late Extraneural Metastases to the Mediastinum

JIM - high impact case reports, 2014-04, Vol.2 (2), p.2324709614532798-2324709614532798

2014

Volltextzugriff (PDF)

Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB/II study

American journal of hematology, 2022-01, Vol.97 (1), p.E24-E27

2022

Volltextzugriff (PDF)

Outreach: Preliminary safety and efficacy results from a phase 2 study of lisocabtagene maraleucel (liso-cel) in the nonuniversity setting

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e19513-e19513

2021

Volltextzugriff (PDF)

Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7062-7062

2022

Volltextzugriff (PDF)

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma

Clinical lymphoma, myeloma and leukemia, 2018-08, Vol.18 (8), p.e327-e331

2018

Volltextzugriff (PDF)

Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)

Blood, 2021-11, Vol.138 (Supplement 1), p.1762-1762

2021

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(72)

Publikationsform

Artikel
(77)

Sprache

Englisch
(77)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Humans
(21)
Adult
(15)
Middle Aged
(14)
Female
(13)
Male
(13)
Oncology
(12)
Aged
(11)
Hematology
(10)
Aged, 80 And Over
(6)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(6)
Biological And Medical Sciences
(6)
Medical Sciences
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Patients
(5)
Lymphoma
(4)
Pharmacology. Drug Treatments
(4)
Treatment Outcome
(4)
Chemotherapy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma

A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy

A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia

Self-reported adherence to lenalidomide as maintenance therpay for multiple myeloma after autologous stem cell transplantation

Myositis-like Chronic Graft Versus Host Disease: Case Series and Literature Review

ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens

Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes

Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3

Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study

Comparison of Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation of G-CSF-Stimulated Bone Marrow Versus Non-Stimulated Bone Marrow Versus Peripheral Blood

A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial)

Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study

Medulloblastoma in an Adult With Late Extraneural Metastases to the Mediastinum

Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB/II study

Outreach: Preliminary safety and efficacy results from a phase 2 study of lisocabtagene maraleucel (liso-cel) in the nonuniversity setting

Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma

Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)

Suchergebnisse filtern